Physician profile
David Eric Schoenfeld
NPI 1184622946
$9,575.17
in general payments reported to CMS, 2019-2025
29 companies · $968 in 2025
The $968 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,741 · 2020: $1,315 · 2021: $1,388 · 2022: $1,362 · 2023: $1,156 · 2024: $1,646 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,769.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,525.41 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,041.20 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,016.70 | 2019-2025 | |
| Ucb, INC. | $816.38 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $622.66 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $596.76 | 2019-2025 | Odomzo, Blu-U, Winlevi |
| Lilly USA, LLC | $568.23 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $517.99 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $499.19 | 2019-2024 | Dupixent, Libtayo |
| Pfizer INC. | $419.00 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $341.91 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Amgen INC. | $213.38 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $203.84 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $196.21 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $181.63 | 2022-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $145.22 | 2019 | |
| Galderma Laboratories, L.P. | $125.12 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $107.90 | 2023-2024 | Zoryve |
| Genentech USA, INC. | $106.09 | 2019-2024 | Erivedge |
| Botanix Sb INC | $71.55 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $55.74 | 2020 | |
| Almirall LLC | $53.62 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $48.31 | 2019-2020 | |
| Kerecis Limited | $25.79 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Surgenex LLC | $24.01 | 2025 | Renograft, Surgraft, Surmatrix |
| Celgene Corporation | $22.94 | 2019 | |
| Medtronic, INC. | $16.22 | 2022 | |
| Dermira, INC. | $12.17 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schoenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.